🇺🇸 FDA
Patent

US 12102642

Treatment of hypercoagulopathy in Cushing's syndrome by administration of glucocorticoid receptor modulators

granted A61KA61K31/4745A61K31/567

Quick answer

US patent 12102642 (Treatment of hypercoagulopathy in Cushing's syndrome by administration of glucocorticoid receptor modulators) held by Corcept Therapeutics Incorporated expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Corcept Therapeutics Incorporated
Grant date
Tue Oct 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K31/4745, A61K31/567, A61K45/06, A61P